Tempus AI stock is preparing for an initial public offering (IPO) and we have all of the details that traders need to know about before it gets here.
Let’s get into all of the latest Tempus AI IPO details below ahead of its potential listing this week!
Tempus AI IPO News
- First off, traders will note that Tempus AI wants to list its shares on the Nasdaq.
- This would see the shares trade under the TEM stock ticker.
- The company is currently planning to price its shares between $35 and $37 apiece.
- It’s also planning to sell a total of 11.1 million shares in the IPO.
- This would result in Tempus raising as much as $410 million from the public offering of TEM stock.
- This would also see the valuation of the company come in at around $6.2 billion.
- Investors will also keep in mind that Tempus AI is backed by Japanese financial firm SoftBank (OTCMKTS:SFTBY).
- The Tempus AI IPO has been in the works for several years now.
- This started when the company sent a confidential filing to the U.S. Securities and Exchange Commission (SEC) for its IPO in September 2021.
- One thing traders will want to know about Tempus AI is that it hasn’t yet turned a profit.
- The company also competes in the healthcare sector with its large collection of clinical and molecular oncology data.
Investors looking for more of the most recent stock market stories are going to want to stick around!
We have all of the hottest stock market news that traders need to know about on Monday! Among that is what’s happening with shares of SoundHound AI (NASDAQ:SOUN) stock, an American deficit warning and more. All of this info is ready at the following links!
More Stock Market News for Monday
- SOUN Stock Alert: SoundHound AI Pays Off Debt Early
- American Deficit Crisis: Why the IMF Is Urging U.S. to Cut its Debts
- Why Is Tonix Pharmaceuticals (TNXP) Stock Down 31% Today?
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
